

James A Watson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/250569/publications.pdf>

Version: 2024-02-01

53
papers

2,006
citations

471509

17
h-index

289244

40
g-index

74
all docs

74
docs citations

74
times ranked

4855
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2030-2040. | 27.0 | 1,013 |
| 2 | COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. <i>PLoS Medicine</i> , 2020, 17, e1003252. | 8.4 | 86 |
| 3 | Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1094-1099. | 1.4 | 77 |
| 4 | Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. <i>Nature Communications</i> , 2019, 10, 5595. | 12.8 | 70 |
| 5 | Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. <i>Clinical Infectious Diseases</i> , 2018, 67, 1543-1549. | 5.8 | 52 |
| 6 | Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. <i>Clinical Infectious Diseases</i> , 2019, 68, 1311-1319. | 5.8 | 49 |
| 7 | Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006440. | 3.0 | 45 |
| 8 | Modelling primaquine-induced haemolysis in G6PD deficiency. <i>ELife</i> , 2017, 6, . | 6.0 | 38 |
| 9 | The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. <i>BMC Medicine</i> , 2019, 17, 151. | 5.5 | 34 |
| 10 | Non-adherence in non-inferiority trials: pitfalls and recommendations. <i>BMJ</i> , The, 2020, 370, m2215. | 6.0 | 29 |
| 11 | Approximate Models and Robust Decisions. <i>Statistical Science</i> , 2016, 31, . | 2.8 | 27 |
| 12 | Investigating causal pathways in severe falciparum malaria: A pooled retrospective analysis of clinical studies. <i>PLoS Medicine</i> , 2019, 16, e1002858. | 8.4 | 26 |
| 13 | A molecular barcode to inform the geographical origin and transmission dynamics of Plasmodium vivax malaria. <i>PLoS Genetics</i> , 2020, 16, e1008576. | 3.5 | 24 |
| 14 | Concomitant Bacteremia in Adults With Severe Falciparum Malaria. <i>Clinical Infectious Diseases</i> , 2020, 71, e465-e470. | 5.8 | 22 |
| 15 | Protective effect of Mediterranean-type glucose-6-phosphate dehydrogenase deficiency against Plasmodium vivax malaria. <i>ELife</i> , 2021, 10, . | 6.0 | 22 |
| 16 | Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision. <i>ELife</i> , 2021, 10, . | 6.0 | 22 |
| 17 | Concentration-dependent mortality of chloroquine in overdose. <i>ELife</i> , 2020, 9, . | 6.0 | 21 |
| 18 | Age, exposure and immunity. <i>ELife</i> , 2018, 7, . | 6.0 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 3.2 | 17 |
| 20 | Split dosing of artemisinins does not improve antimalarial therapeutic efficacy. <i>Scientific Reports</i> , 2017, 7, 12132. | 3.3 | 16 |
| 21 | Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, . | 3.2 | 16 |
| 22 | A decision-theoretic approach to the evaluation of machine learning algorithms in computational drug discovery. <i>Bioinformatics</i> , 2019, 35, 4656-4663. | 4.1 | 15 |
| 23 | Collider bias and the apparent protective effect of glucose-6-phosphate dehydrogenase deficiency on cerebral malaria. <i>ELife</i> , 2019, 8, . | 6.0 | 15 |
| 24 | Tafenoquine for the prevention of <i>Plasmodium vivax</i> malaria relapse. <i>Lancet Microbe</i> , The, 2021, 2, e175-e176. | 7.3 | 13 |
| 25 | Characterizing Blood-Stage Antimalarial Drug MIC Values <i>In Vivo</i> Using Reinfection Patterns. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, . | 3.2 | 12 |
| 26 | Prediction of disease severity in young children presenting with acute febrile illness in resource-limited settings: a protocol for a prospective observational study. <i>BMJ Open</i> , 2021, 11, e045826. | 1.9 | 12 |
| 27 | Machine learning analysis plans for randomised controlled trials: detecting treatment effect heterogeneity with strict control of type I error. <i>Trials</i> , 2020, 21, 156. | 1.6 | 11 |
| 28 | Stopping prereferral rectal artesunate â€” a grave error. <i>BMJ Global Health</i> , 2022, 7, e010006. | 4.7 | 11 |
| 29 | Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with <i>Plasmodium vivax</i> Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0130221. | 3.2 | 10 |
| 30 | The probability of a sequential <i>Plasmodium vivax</i> infection following asymptomatic <i>Plasmodium falciparum</i> and <i>P. vivax</i> infections in Myanmar, Vietnam, Cambodia, and Laos. <i>Malaria Journal</i> , 2019, 18, 449. | 2.3 | 7 |
| 31 | Characterizing variation of nonparametric random probability measures using the Kullbackâ€”Leibler divergence. <i>Statistics</i> , 2017, 51, 558-571. | 0.6 | 5 |
| 32 | A semi-supervised learning framework for quantitative structureâ€”activity regression modelling. <i>Bioinformatics</i> , 2021, 37, 342-350. | 4.1 | 5 |
| 33 | The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. <i>Wellcome Open Research</i> , 2021, 6, 71. | 1.8 | 5 |
| 34 | A cautionary note on the use of unsupervised machine learning algorithms to characterise malaria parasite population structure from genetic distance matrices. <i>PLoS Genetics</i> , 2020, 16, e1009037. | 3.5 | 5 |
| 35 | Methaemoglobinaemia and the radical curative efficacy of 8â€”aminoquinoline antimalarials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2657-2664. | 2.4 | 5 |
| 36 | Rejoinder: Approximate Models and Robust Decisions. <i>Statistical Science</i> , 2016, 31, . | 2.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. Wellcome Open Research, 2021, 6, 71. | 1.8 | 4 |
| 38 | A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: Application to a dose-finding trial for a novel Russell's viper antivenom in Myanmar. PLoS Neglected Tropical Diseases, 2020, 14, e0008109. | 3.0 | 4 |
| 39 | Graphing and reporting heterogeneous treatment effects through reference classes. Trials, 2020, 21, 386. | 1.6 | 3 |
| 40 | Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2022, 112, 824-835. | 4.7 | 3 |
| 41 | Antimalarial Resistance Unlikely To Explain U.K. Artemether-Lumefantrine Failures. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 1 |
| 42 | Time-to-death is a potential confounder in observational studies of blood transfusion in severe malaria. Lancet Haematology,the, 2021, 8, e12. | 4.6 | 1 |
| 43 | Falciparum malaria mortality in sub-Saharan Africa in the pretreatment era. Trends in Parasitology, 2021, , . | 3.3 | 1 |
| 44 | Questioning the Claimed Superiority of Malaria Parasite Ex Vivo Viability Reduction Over Observed Parasite Clearance Rate?. Journal of Infectious Diseases, 2021, 224, 738-739. | 4.0 | 0 |
| 45 | Severe malaria, Pascalian therapeutics and the US FDA. Clinical Infectious Diseases, 2022, , . | 5.8 | 0 |
| 46 | Title is missing!. , 2020, 16, e1009037. | | 0 |
| 47 | Title is missing!. , 2020, 16, e1009037. | | 0 |
| 48 | Title is missing!. , 2020, 16, e1009037. | | 0 |
| 49 | Title is missing!. , 2020, 16, e1009037. | | 0 |
| 50 | Title is missing!. , 2020, 14, e0008109. | | 0 |
| 51 | Title is missing!. , 2020, 14, e0008109. | | 0 |
| 52 | Title is missing!. , 2020, 14, e0008109. | | 0 |
| 53 | Title is missing!. , 2020, 14, e0008109. | | 0 |